Growth Hormone and Endometrial Receptivity

Area of Science:

• Reproductive Endocrinology
• In Vitro Fertilization (IVF)
• Endocrinology

Background:

• Growth hormone (GH) administration during ovarian stimulation is linked to improved in vitro fertilization (IVF) outcomes.
• The primary mechanism was thought to be enhanced oocyte quality.
• Emerging evidence suggests a potential role for GH in improving endometrial receptivity.

Purpose of the Study:

• To review current data on the effects of co-administering GH during IVF on endometrial receptivity.
• To explore the potential benefits of GH for infertile women, particularly those with recurrent implantation failure, thin endometrium, or advanced maternal age.
• To propose mechanisms by which GH may influence endometrial function.

Main Methods:

• Literature review of recent studies investigating GH co-treatment in IVF.
• Analysis of data focusing on endometrial receptivity markers and clinical outcomes.
• Synthesis of proposed molecular and cellular mechanisms of GH action in the endometrium.

Main Results:

• GH administration may positively impact endometrial receptivity, offering a potential benefit beyond oocyte quality.
• This effect is particularly relevant for specific patient groups undergoing IVF, including those with implantation difficulties or thin endometria.
• Several mechanisms are proposed for GH's action on the endometrium, including modulation of growth factors and inflammatory pathways.

Conclusions:

• Growth hormone may enhance endometrial receptivity, contributing to improved IVF success rates.
• GH co-treatment presents a potential therapeutic strategy for infertile women with specific reproductive challenges.
• Further research is warranted to elucidate the precise mechanisms and optimize GH application in assisted reproductive technologies.